Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 34,423 | 36,594 | 10,489 | 9,715 | 5,099 |
| TOTAL | $34,510 | $36,745 | $10,687 | $9,742 | $5,187 |
| Non-Current Assets | |||||
| PPE Net | 2 | 3 | 3 | 5 | 6 |
| Investments And Advances | 63 | 130 | 0 | 0 | 0 |
| Intangibles | 19 | 21 | 23 | 24 | 26 |
| Other Non-Current Assets | 0 | 0 | 0 | 6 | 6 |
| TOTAL | $84 | $154 | $26 | $35 | $38 |
| Total Assets | $34,594 | $36,899 | $10,713 | $9,777 | $5,225 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 665 | 486 | 762 | 377 | 285 |
| Accrued Expenses | 1,413 | 1,451 | 1,651 | 1,226 | 1,129 |
| TOTAL | $2,147 | $1,937 | $2,486 | $1,603 | $1,493 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 1 | 5 |
| TOTAL | $N/A | $N/A | $N/A | $1 | $5 |
| Total Liabilities | $2,147 | $1,937 | $2,486 | $1,604 | $1,498 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 22,043 | 21,908 | 21,933 | 18,312 | 16,878 |
| Common Shares | 22 | 22 | 18 | 18 | 16 |
| Retained earnings | -111,104 | -107,373 | -101,965 | -98,850 | -95,131 |
| Other shareholders' equity | 7,290 | 7,283 | 7,333 | 7,505 | 7,448 |
| TOTAL | $32,447 | $34,962 | $8,227 | $8,173 | $3,727 |
| Total Liabilities And Equity | $34,594 | $36,899 | $10,713 | $9,777 | $5,225 |